Clinical Study

A study of 180 days or more is recommend by Study Investigator and Study Coordinator in order to validate rate of effectiveness however these study results do indicate Procerin to be an effective nutritional therapy for thinning hair. 90% of those that completed the study stated a level of satisfaction with the product, most after 90 days with a majority using the descriptors 'thicker' and 'more full'.

93.75% of those in the study with opinions agreed that Procerin helped to slow their hair loss (see Graph 2) and 93% of those with opinions stated they would recommend it to friends and family.

Procerin Research Study Summary

Detuag Testing, Inc conducted an IRB Approved Research Study for Speedwinds Nutrition, Inc designed to document a user’s rate of result* and to solicit user feedback on the use of an ingested and a topically applied nutritional therapy for hair growth. Speedwinds Nutrition inc. is selling the product as a single product branded Procerin. The results* of this study will help Speedwinds Nutrition, Inc document user reaction to product effectiveness and provides user feedback information including user’s level of satisfaction. For specific objectives related to this study, please refer to the section titled "Objectives".

Detuag Testing, Inc. expected to enroll up to 50 subjects in the study. A minimum of 30 subjects were expected to complete 60 days of the trial and a minimum of 20 were expected to complete the 90 day trial. The study recruitment goals were met per the complete 90 day study.

The study coordinator initially enrolled 32 participants in the study with a total of 21. Participants completing the full 90 days.

The study was monitored by a licensed dermatologist. Participants completed a registration questionnaire as well as an informed consent prior to enrolling in the trial. Participants were expected to complete a diary, questionnaires, have their photos taken and participate in focus groups and interviews. Participants were compensated for their participation in the trial.

Procerin Research Study Background

Product Description

Procerin comes in a convenient tablet form and topical foam that are used in combination daily for the nutritional therapy of male hair loss. Procerin is a natural supplement available without a prescription. While there are several causes of hair loss, Procerin (topical and tablet together) is effective in reversing hair loss in some men caused by androgenetic alopecia, the most common cause of male hair loss. Androgenetic Alopecia (AGA) results* in thinning hair and the familiar receding hairline (or widow's peak.) AGA afflicts approximately 50% of men over the age of 40. It is characterized by a progressive miniaturization of scalp hair follicles in predisposed individuals. AGA hair loss involves a genetically predetermined sensitivity to the effects of the androgenic hormone dihydrotestosterone, or DHT, in certain scalp hair follicles. DHT is believed to shorten the growth, or anagen, phase of the hair cycle, causing the miniaturization of the follicles.

Speedwinds Nutrition, Inc. has developed this combination of supplements formulated with natural ingredients known to block production of DHT, a major cause of hair loss in men. The active product ingredients illustrated in figure 1 are known DHT inhibitors and are found in the topical foam and nutritional supplement. Illustrated in figure 2 is product ingredient list.

Figure 1:

Figure 2:

Active ingredients in Procerin have had supportive studies relating to hair growth and or the blocking of DHT.

The prominent active ingredients of Procerin have been proven to help block DHT (DHT is the chemical which is said to cause hair loss in men) and combat the effects of hair loss and thinning hair. The Procerin package will be positioned as a dietary supplement and topical which slows hair loss and promotes regrowth.

Clinical Support:

A Randomized, Double-Blind, Placebo-Controlled Trial to Determine the Effectiveness of Botanically Derived Inhibitors of 5-alpha-Reductase in the Treatment of Androgenetic Alopecia published in The Journal of Alternative and Complementary Medicine resulted* in the demonstration of a positive response for the active ingredients utilized in Procerin and other DHT inhibiting dietary supplements currently on the market. (The Journal of Alternative and Complementary Medicine. 2002, 8(2): 143-152.)

Other proprietary ingredients like Gotu Kola are known to increase blood flow, Nettles are known as an anti-inflammatory and have been used to alter the same mechanism that affect the aging prostate as those in hair loss. Most of the ingredients in Procerin have been shown to assist in hair growth in one way or another.

The clinical trials submitted to the FDA provide strong evidence as to the Procerin product’s efficacy and safety. The same is reported in this Research Study. There were no reported serious adverse events during the Procerin study nor are they expected in the post-study follow-up.

Objectives

The key objectives of this study were to:

1. Solicit user feedback on the Procerin use.
2. Solicit user feed back on any side effect.
3. Solicit user feedback on key benefits and key challenges of the Procerin combination use.
4. Solicit user feedback into labeling, packaging, and instructions.
5. Solicit user feedback on individual experience of product effectiveness.
6. Solicit any photographic evidence of efficacy over 90 days.

Procerin Research Study Population & Screening

All participants in the trial were to meet the Inclusion Criteria listed below.

Recruitment Criteria

A Telephone Screener document was prepared and can be found in Appendix 1.

Inclusion Criteria

Subjects were included in the study if they satisfied the following:

1. Males between the ages of 18 and 50 years of age.
2. In good health, with mild to moderate AGA.

Exclusion Criteria

Criteria for Exclusion Prior to the Start of the Study:

1. Those that are unemployed as unemployed men do not represent the targeted consumer;
2. Those who had been on prescription or over-the-counter use for AGA or a Prostate condition within the past 30 days prior to initiation of the trial;
3. Symptomatic cardiac problems, uncontrolled hypertension, symptomatic hypotension, autoimmune disorders;
4. Those who had participated in a clinical trial within 30 days prior to Enrollment
5. Those with any known allergy to any ingredients in the test products
6. Those who are currently taking a MAOI inhibitor
7. Those with any other medical condition that could interfere with successful conclusion of the study.

Criteria for Exclusion during the Study. Date of termination of participant in the study will be recorded.

• Grave illness during use. Any subject with a new diagnosis of a grave illness during the study trial will be immediately terminated from the trial. The date of termination from the study will be recorded.
• Non-compliance.
• Sunburn over entire head is reason for exclusion from the study. Subjects will be advised to avoid over exposure to sun during the use period and for at least two (2) weeks afterwards.

Screening

All participants in the trial met the Inclusion and Exclusion Criteria listed below. These participants were drawn from specific demographic / psychographic segments based on the following criteria.

Subjects were compensated $25per weekday visit and [$50] for attending any follow-on meetings, focus groups or interviews.

Recruitment Summary

Large Ads were placed in various daily newspapers designed to attract those that suffer from AGA (see Appendix 2 and see Appendix 3).

• 32 participants met the criteria and were invited to participate in the study
• 21 completed the protocol for 90 day study

Research Study Methodology

Once a potential participant passed the telephone screen, a screening visit was scheduled and if the subject fulfilled all inclusion criteria, the subject was enrolled as a subject and completed the Screening Visit procedure described below. This visit served as the baseline visit.

Screening Visit

At the Screen/Baseline Visit (study day 1), the following was performed:

1. Informed consent was explained and obtained.
2. Subject questionnaire was completed containing subject name, contact information, hair history, pertinent medical history, medications, and allergies.
3. Site investigator or study coordinator reviewed the questionnaire for completion of information and signature and answer all questions by subject. The Principal Investigator, a qualified medical doctor, made the final decision for inclusion or exclusion of a subject into the study based on examination and the subject’s medical history, medications, or allergies.
4. After qualification for inclusion in the study, subjects were assigned sequential registration number by the site coordinator beginning with 900. Assignments were made on time of first presentation, a first-come first-served basis, regardless of age, gender, heritage, severity of hair loss, or any other criteria.
5. Subject "before" photos were then taken.
6. Each subject was provided a Subject Package (shown in Appendix 4) including:
   1. Supplement bottles. The investigator attached a sticker to the back of the product with the registration number which remained in place throughout the study.
   2. Procerin User’s directions
   3. Study Directions;
   4. Subject Diary;
   5. Copy of Informed Consent;
7. Subject was instructed to review Procerins user guide and answer a brief questionnaire prior to using the product
8. Overall hair assessment was made using a Norwood-Hamilton Scale of male baldness

   (Table I). Norwood-Hamilton Scale of Male Pattern Baldness

   
9. Throughout the study subjects were asked to evaluate any change with respect to their current level of satisfaction with their hair.
10. A representative area of baldness on the scalp vertex will be selected and a small dot will be tattooed with permanent ink in the center of the balding area and a ½ inch diameter circle template will be cut from a plastic material. At every other visit the template will be placed centered over the dot and noticeable hairs will be counted. This was found to be inconclusive and was discontinued early on as the accuracy of the hair counts are questionable being that hairs which fell on the borderline may have fallen within or outside of the perimeter on a given day.

Follow-UP Visits

Subjects came in every week. Each Follow-On Visit consisted of the following:

• Any adverse events were noted in the subject chart and reported per the On-Site Study procedures.
• Subject photos taken and documented with use day.
• Review prior week’s diary and determine compliance.
• Address any subject questions.
• Any significant deviations from the use procedure or any material questions from the subject will be noted in the subject chart.
• Subjects were asked to evaluate any change with respect to their current level of satisfaction with the product use.
• At the end of the study subjects were asked to complete the Procerin Exit Questionnaire shown in Appendix 4.
• All subjects were instructed to use the Procerin nutritional supplement tablet and topical solution in their daily regimen.
• Subjects were able to opt out at any time.

Procerin Nutritional supplement and topical supplement
Week 00	Saturday
Week 01	Wed/Thurs
Week 02	Wed/Thurs
Week 03	Wed/Thurs
Week 04	Wed/Thurs
Week 05	Wed/Thurs
Week 06	Wed/Thurs
Week 07	Wed/Thurs
Week 08	Wed/Thurs
Week 09	Wed/Thurs
Week 10	Wed/Thurs
Week 11	Wed/Thurs
Week 12	Wed/Thurs
Week 13	Wed/Thurs

Final Visit and Study End Points

At the end of each subject’s study period, the subjects returned all study materials provided to them with the exception of the following:

• Their copy of the Informed Consent

Compensation

Subjects who complete the study will be compensated $25 for each office visit. Subjects will also be compensated $50 for attending any individual interviews. All payments will be made 30 days after completion by check by study sponsor.

Conclusion

In order to test the full impact on the hair follicle’s growth cycle at least 6 months would be required however the results* of this initial 90 day Procerin Research study indicates that Procerin generates positive results* for Men. 90% of the subjects’ perception was that Procerin did slow hair loss. Moreover, the data shows that the vast majority of subjects are satisfied with Procerin and would recommend it to others. The majority of hair loss products on the market used to contain minoxodil, a drug that alters blood flow and is helpful for vertex balding. Then science noticed that medications that were used to shrink the aging enlarged prostate started to grow hair in men not only in the vertex but frontally as well. This led to the laboratory discovery of DHT receptor blockers. Herbal medications, that at the turn of the century were initially used to improve elderly urine flow, were now being looked at for prostatic and hair growth uses. There is a need to incorporate both the blood flow and DHT blocking abilities in a therapy that is easy to use and holistic in nature without prescriptive medication side effects. Procerin fits this bill nicely. This study clearly shows Procerin therapy is easy to use and even has beneficial photographic results* at 90 days.

List of Appendices

References

1: Dermatol Surg. 1998 Dec;24(12):1330-2.Links
Prevalence of male pattern hair loss in 18-49 year old men.
Rhodes T, Girman CJ, Savin RC, Kaufman KD, Guo S, Lilly FR, Siervogel RM, Chumlea WC.
Department of Epidemiology, Merck Research Laboratories, West Point, PA 19486, USA.

LIST OF APPENDICES

1. Telephone Screener
2. Recruitment Ad a
3. Recruitment Ad b
4. Procerin Exit Questionnaire